TrialInternational journal of hematology2012

An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).

Yukari Shirasugi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.